New nasal COVID vaccine could replace needles
NCT ID NCT07416539
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new nasal spray vaccine called COV2 against COVID-19. Twenty healthy adults who have already had at least two COVID-19 shots will receive two doses of one of two formulations. The study aims to check if the vaccine is safe and whether it boosts the body's immune defenses against the Omicron BA.5 variant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
COV2 vaccine (nasal spray, adenoviral vector-based)
What this could lead to
If successful, this could lead to a needle-free COVID-19 vaccine that may be easier to administer and could boost immunity against variants.
What could go wrong
This is a very early Phase 1 trial with only 20 participants, so safety and immune response are still unproven. The vaccine may not work as hoped or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kuopio University Hospital, ENT policlinic
RECRUITINGKuopio, Northern Savonia, 70210, Finland
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••